Quantum-Si incorporated (QSI) AI Stock Analysis

Quantum-Si Incorporated is a life sciences company specializing in the development of a single molecule detection platform tailored for sample preparation and sequencing. Founded in 2013 and based in Guilford, Connecticut, the company utilizes semiconductor-based methodologies to advance proteomics and enable next-generation protein sequencing. Its platform is designed to transform how proteins are analyzed and sequenced, delivering insights into biological processes, disease mechanisms, precision medicine, diagnostics, and therapeutic development.

Quantum-Si grew revenue from $459,000 in FY2022 to $1.1M in FY2023 and $3.1M in FY2024, representing a 3-year compound annual growth rate of 74.4% through FY2025. However, revenue fell 20.3% in FY2025 to $2.4M. Gross margin improved from -563.0% in FY2022 to 52.3% in FY2024 before settling at 47.3% in FY2025. Substantial research spending, including $53.8M in FY2025 R&D expenses, kept operating margin at -3996.7% and net income at -$101.3M. For the trailing twelve months ended June 30, 2026, revenue stood at $1.6M with quarterly revenue down 41.8% year-over-year.

As of June 30, 2026, Quantum-Si held $111.7M in cash and short-term investments against total debt of $3.3M, yielding a net cash position of $108.5M. Liquidity is supported by a current ratio of 9.97 and a debt-to-equity ratio of 0.02. In FY2025, the company used $94.7M in operating cash flow and invested $2.5M in capital expenditures, resulting in free cash flow of -$97.2M. Over the past five years, the diluted share count increased by 58.6%.

Quantum-Si trades at a price-to-sales multiple of 152.7x and an enterprise value to revenue multiple of 36.0x, substantially higher than the median of its US-listed Healthcare peers at 4.1x sales. Its price-to-book ratio is 0.9x, and enterprise value to EBITDA sits at 0.6x compared to 12.0x for the peer group median. Over the past year, the stock fell 55.9% while the S&P 500 gained 16.8%, and its five-year return of -87.0% trailed the S&P 500 return of 83.0%.

Wall Street coverage includes 2 Strong Buy ratings and 1 Hold rating, with zero Sell recommendations. The mean price target of $2.30 represents a 105.4% premium over the last close of $1.12. For the fiscal year ending December 31, 2026, analysts estimate revenue of $1.1M and an EPS of -$0.40. For the following fiscal year, 1 analyst projects revenue to reach $5.8M with an EPS of -$0.35. The company beat EPS expectations in 3 of the last 4 quarters, with its next earnings scheduled for November 4, 2026.

This page is an AI-written research summary of Quantum-Si incorporated (QSI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: QSI income statement, QSI balance sheet, QSI key metrics, QSI analyst forecast, QSI chart. See the QSI stock overview for the latest quote and news.